THE     BLOG

Only 2% of novel analgesics will make it through clinical development. Understanding the development process for an individual pain...

Key differences in pain mechanisms between preclinical species and humans have hindered the development of new analgesics. Recent...

A newly published article "RNA profiling of human dorsal root ganglia reveals sex-differences in mechanisms promoting neuropathic pain"...

Vertex are looking to other therapeutic areas to repeat their undoubted success in Cystic Fibrosis and create a sustainable pipeline....

Increasing innovation within analgesic R&D is key to identify new treatment options for millions of pain patients. I am delighted...

Yesterday (25th Aug 2020) saw the announcement that ACADIA Pharmaceuticals acquires privately held Dallas, TX-based CerSci Therapeutics,...

"Unity Biotechnology announced the 12-week results from the Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with...

Back in January 2020 the FDA had a number of expert panels voting on opioid drugs – ultimately giving negative feedback for the class. So...

Nice guidance on chronic pain creates wrong messages and potentially stops patients receiving life altering medication. This week NICE...

Targeting the right patient population in clinical trials is key to avoiding a false negative and giving a medicine the best chance of...

The last annual report for Biogen indicates worrying signs for the future development of the latest stage Nav1.7 compound Vixotrigine.

Presentation by Mark J. Field at SMI Pain Therapeutics Meeting 12th May 2020. You can find a copy of the presentation above. It covers...

"Citizen science" is defined as "scientific work undertaken by members of the general public, often in collaboration with or under the...

P2X3 receptor channels are attractive therapeutic targets as they are expressed in sensory neurons, activated by extracellular ATP and...

I believe LinkedIn is a great source for keeping up to date with content which can be tailored to be most relevant to you. Over the past...

The traditional approach to analgesic development could be described as 'exceptionally challenging', with a clinical success rate of...

The difficulties of pain research are highlighted well by the tale of the Nav1.7 sodium channel, which was thought to be the ‘holy grail’...

Just a few months ago some commentators had pronounced the death of Tanezumab and the whole anti-NGF class it leads, following years of...

Deep within the Full-Year and Fourth-Quarter 2019 Financial Results for Vertex you can find this statement: “Pain: The company announced...

The probability of a new analgesic making it through clinical development is 2%. Five-times lower than other therapeutic areas. This...